Preparation, characterization, and anticancer efficacy of evodiamine-loaded PLGA nanoparticles

References

• Acharya S, Sahoo SK. (2011). PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 63:170–83
   PubMed Web of Science ®Google Scholar
• Anderson JM, Shive MS. (1997). Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28:5–24
   PubMed Web of Science ®Google Scholar
• Beral V, Banks E, Reeves G, et al. (2003). Breast cancer and hormone-replacement therapy: the Million Women Study. Lancet 362:1330–1
   Web of Science ®Google Scholar
• Bunnell TM, Burbach BJ, Shimizu Y, Ervasti JM. (2011). β-Actin specifically controls cell growth, migration, and the G-actin pool. Mol Biol Cell 22:4047–58
   PubMed Web of Science ®Google Scholar
• Chazotte B. (2010). Labeling cytoskeletal F-actin with rhodamine phalloidin or fluorescein phalloidin for imaging. Cold Spring Harbour Protocol 2010:pdb.prot4947
   Google Scholar
• Chen F, Li S, Li D, et al. (2012). Transdermal behaviors comparisons among Evodia rutaecarpa extracts with different purity of evodiamine and rutaecarpine and the effect of topical formulation in vivo. Fitoterapia 83:954–60
   PubMed Web of Science ®Google Scholar
• Chen MC, Yu CH, Wang SW, et al. (2010). Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO. J Cell Biochem 110:1495–503
   PubMed Web of Science ®Google Scholar
• Chung Y-I, Kim JC, Kim YH, et al. (2010). The effect of surface functionalization of PLGA nanoparticles by heparin-or chitosan-conjugated Pluronic on tumor targeting. J Control Release 143:374–82
   PubMed Web of Science ®Google Scholar
• Cooper JA. (1987). Effects of cytochalasin and phalloidin on actin. J Cell Biol 105:1473–8
   PubMed Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, et al. (2012). PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161:505–22
   PubMed Web of Science ®Google Scholar
• Dong G, Wang S, Miao Z, et al. (2012). New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure–activity relationship analysis and biological evaluations. J Med Chem 55:7593–613
   PubMed Web of Science ®Google Scholar
• Du J, Wang XF, Zhou QM, et al. (2013). Evodiamine induces apoptosis and inhibits metastasis in MDAMB-231 human breast cancer cells in vitro and in vivo. Oncol Rep 30:685–94
   PubMed Web of Science ®Google Scholar
• Fei XF, Wang BX, Li TJ, et al. (2003). Evodiamine, a constituent of Evodiae Fructus, induces anti-proliferating effects in tumor cells. Cancer Sci 94:92–8
   PubMed Web of Science ®Google Scholar
• Huang DM, Guh JH, Huang YT, et al. (2005). Induction of mitotic arrest and apoptosis in human prostate cancer pc-3 cells by evodiamine. J Urol 173:256–61
   PubMed Web of Science ®Google Scholar
• Huang YC, Guh JH, Teng CM. (2004). Induction of mitotic arrest and apoptosis by evodiamine in human leukemic T-lymphocytes. Life Sci 75:35–49
   PubMed Web of Science ®Google Scholar
• Jiang J, Hu C. (2009). Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules 14:1852–9
   PubMed Web of Science ®Google Scholar
• Khalil NM, do Nascimento TCF, Casa DM, et al. (2013). Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf B Biointerfaces 101:353–60
   PubMed Web of Science ®Google Scholar
• Kimura K, Hirano M, Kobayashi R, et al. (1998). Phosphorylation and activation of 13S condensin by Cdc2 in vitro. Science 282:487–90
   PubMed Web of Science ®Google Scholar
• Li M, Rouaud O, Poncelet D. (2008). Microencapsulation by solvent evaporation: state of the art for process engineering approaches. Int J Pharm 363:26–39
   PubMed Web of Science ®Google Scholar
• Li-Weber M. (2013). Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett 332:304–12
   PubMed Web of Science ®Google Scholar
• Manchanda R, Fernandez-Fernandez A, Nagesetti A, et al. (2010). Preparation and characterization of a polymeric (PLGA) nanoparticulate drug delivery system with simultaneous incorporation of chemotherapeutic and thermo-optical agents. Colloids Surf B Biointerfaces 75:260–7
   PubMed Web of Science ®Google Scholar
• Mukerjee A, Vishwanatha JK. (2009). Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res 29:3867–75
   PubMed Web of Science ®Google Scholar
• Rasul A, Yu B, Zhong L, et al. (2012). Cytotoxic effect of evodiamine in SGC-7901 human gastric adenocarcinoma cells via simultaneous induction of apoptosis and autophagy. Oncol Rep 27:1481–7
   PubMed Web of Science ®Google Scholar
• Rubtsova SN, Kondratov RV, Kopnin PB, et al. (1998). Disruption of actin microfilaments by cytochalasin D leads to activation of p53. FEBS Lett 430:353–7
   PubMed Web of Science ®Google Scholar
• Schwarz NA, Spillane M, La Bounty P, et al. (2013). Effects of capsaicin and evodiamine ingestion on energy expenditure and fat oxidation at rest and after moderately-intense exercise in young men. International Journal of Exercise Science: Conference Proceedings, Vol. 2, Article 11
   Google Scholar
• Takada Y, Kobayashi Y, Aggarwal BB. (2005). Evodiamine abolishes constitutive and inducible NF-κB activation by inhibiting IκBα kinase activation, thereby suppressing NF-κB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J Biol Chem 280:17203–12
   PubMed Web of Science ®Google Scholar
• Tan Q, Liu S, Chen X, et al. (2012). Design and evaluation of a novel evodiamine-phospholipid complex for improved oral bioavailability. AAPS PharmSciTech 13:534–47
   PubMed Web of Science ®Google Scholar
• Torchilin V. (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63:131–5
   PubMed Web of Science ®Google Scholar
• Xu S, Peng J, Li Y, et al. (2012). Pharmacokinetic comparisons of rutaecarpine and evodiamine after oral administration of Wu-Chu-Yu extracts with different purities to rats. J Ethnopharmacol 139:395–400
   PubMed Web of Science ®Google Scholar
• Yang J, Cai X, Lu W, et al. (2012). Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells. Cancer Lett 328:243–51
   PubMed Web of Science ®Google Scholar
• Yu H, Jin H, Gong W, et al. (2013). Pharmacological actions of multi-target-directed evodiamine. Molecules 18:1826–43
   PubMed Web of Science ®Google Scholar